Respiratory Syncytial Virus Infection Prevention

Respiratory·MeSH: Respiratory Syncytial Virus Infections

10 drugs in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 2(6)

Drug	Company
High dose antigen of LYB005 with A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)
High dose antigen of LYB005 without A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)
Low dose antigen of LYB005 with A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)
Low dose antigen of LYB005 without A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)
Middle dose antigen of LYB005 with A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)
Middle dose antigen of LYB005 without A01B adjuvant	Cidara Therapeutics, Inc. (CDTX)

Phase 4(4)

Drug	Company
High dose potent statin	Cidara Therapeutics, Inc. (CDTX)
Postoperative pain management with acetaminophen	Cidara Therapeutics, Inc. (CDTX)
Postoperative pain management with dexketoprofen	Cidara Therapeutics, Inc. (CDTX)
Postoperative pain management with metamizole	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 10 drugs in development for Respiratory Syncytial Virus Infection Prevention across 1 company.

There are 1 clinical trial targeting Respiratory Syncytial Virus Infection Prevention tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.